First Drug Cenegermin (Oxervate) Approved for Rare Eye Disease
THURSDAY, Aug. 23, 2018 -- Oxervate (cenegermin) has been approved by the U.S. Food and Drug Administration to treat neurotrophic keratitis, a rare disease of the eye's cornea.
The cornea is the clear layer that covers the colored portion at the front of the eye.
Neurotrophic keratitis affects fewer than five in 10,000 people, the FDA said. The disease, causing loss of corneal sensation, leads to damage of this vital part of the eye.
"While the prevalence of neurotrophic keratitis is low, the impact of this serious condition on an individual patient can be devastating," Dr. Wiley Chambers, an ophthalmologist in the FDA's Center for Drug Evaluation and Research, said in an agency news release.
Oxervate, produced as an eyedrop, was evaluated in a clinical study involving 151 people with neurotrophic keratitis. Some participants were given Oxervate, while others were given a placebo eye drop. Complete corneal healing was reported among 70 percent of people treated with Oxervate, compared with 28 percent of those given the placebo, the FDA said.
The most common side effects of the drug included eye pain, enlarged blood vessels in the eye, eye inflammation and watery eyes.
Oxervate is produced by the Italian firm Dompé farmaceutici.
© 2020 HealthDay. All rights reserved.
Posted: August 2018
Read this next
THURSDAY, Aug. 27, 2020 -- If your child will be doing online learning this school year, you need to take steps to protect them from eye strain, the American Academy of...
MONDAY, Aug. 10, 2020 -- Diabetes can wreak havoc on many parts of the body, including the eyes, but people with diabetes aren't doomed to have vision problems. With good blood...
TUESDAY, June 9, 2020 -- Rubber bullets can cause severe eye injuries, blindness and even death, and they shouldn't be used against protesters, claims a petition signed by almost...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.